K
KalVista Pharmaceuticals, Inc. (KALV)
NGM – Real Time Price. Currency in USD
19.33
+0.38 (2.01%)
At close: Mar 27, 2026, 4:00 PM EDT
18.69
-0.64 (-3.31%)
After-hours: Mar 27, 2026, 7:50 PM EDT

NGM – Real Time Price. Currency in USD
19.33
+0.38 (2.01%)
At close: Mar 27, 2026, 4:00 PM EDT
18.69
-0.64 (-3.31%)
After-hours: Mar 27, 2026, 7:50 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.22 | 6.05 | 10 | |
| Quick ratio | 7.21 | 5.63 | 10 | |
| Debt to Equity | 16.62 | 0.30 | 2.0 | |
| Debt to Assets | 0.83 | 1.04 | 2.0 | |
| Interest coverage | -9.68 | -16.91 | 1.0 | |
| Weighted average score | 5.0 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | 15M |
| Gross Profit | -743K | -802K | -816K | -941K | 13M |
| Operating Income | -97M | -111M | -149M | -193M | -203M |
| Net Income | -82M | -93M | -127M | -183M | -210M |
| EBITDA | -96M | -110M | -148M | -192M | -156M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 2497.22 | 55.23 | 10 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | 30.44 | 5.5 |
| Next year | 194.36 | 32.51 | 10 |
| Weighted average score | 6.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 860.17 | 17.66 | 9.82 | N/A | 6.5 |
| Y/Y | 999 | -17.06 | -10.98 | N/A | 3.3 |
| 3y average | 999 | -31.31 | -3.21 | -28.39 | 3.3 |
| 5y average | 779.2 | -46.15 | -19.2 | -42.74 | 3.3 |
| Weighted average score | 4.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $282.6M significantly exceeds cash reserves ($243.5M), raising financial stability concerns
Total current assets $325.2M exceed Total current liabilities $45.1M, highlighting excellent liquidity
Debt-to-equity ratio (16.6) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-9.7x) is dangerously low, suggesting debt repayment risks